Guo Jian-Xin, Zhou Ya-Hong, Guan Rui-Ting, Pan Jing-Xin, Zhang Xue-Ya, Zhong Jin-Fa
Department of Hematology, Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, FuJian Province, China.
Department of Hemodialysis, Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, FuJian Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1235-9. doi: 10.7534/j.issn.1009-2137.2015.05.003.
To explore the expression and promoter CpG island methylation status of miR-34b in leukemia cell lines and their clinical significance.
A total of 10 cases of non-hematologic diseases were selected as control group, and the bone marrow cells of control group and HL-60, K562 cells were selected; the relative expression of miR-34b was detected in bone marrow cells, HL-60 and K562 cell lines by fluorescence quantitative PCR, and the MiR-34b methylation status was detected by methylation-specific PCR, the HL-60 and K562 cell lines were treated with decitabine, and the expression levels and methylation status of miR-34b in the 2 cell lines were detected by the same method. Has-miR-34b was transfected into K562 cells, which were divided into non-transfection group, negative control group and Has-miR-34b transfection group; if the transfection was successful, the cell proliferation should be recorded at different time points of culture, and the proliferation inhibition rate should be calculated.
The relative expression level of miR-34b in the control group was (5.23 ± 0.75), in HL-60 was (0.05 ± 0.01) and in K562 was (0.04 ± 0.01). The difference between 3 groups was statistically significant (F = 44.812, P < 0.01). The promoter regions of CpG island in HL-60 and K562 cell lines were methylated, while the bone marrow cells were not methylated in 10 cases of non hematologic diseases children.Through miR-34b expression levels of HL-60 and K562 cell lines significantly increased by decitabine treatment (P < 0.05), and the methylation of leukemia cell line promoter region CpG island was found before and after decitabine treatment, but after administration of decitabine the methylation significantly decreased, suggesting that decitabine has an inhibitory effect on methylation of promoter region CpG island. After being cultured for 48, 72, 96 and 120 hrs, the cell proliferation in Has-miR-34b transfection group reached to 24.8%, 46.7%, 33.6% and 4.7%, repectively, and significantly lower than that in non transfection group (P < 0.05).
CpG island methylation of miR-34b promoter region in leukemia cell lines can decrease the expression levels of miR-34b, which is also the reason why miR-34b can reduce the inhibition of cell proliferation, thus miR-34b might be a tumor suppressor gene involved in the regulation of leukemia.
探讨miR-34b在白血病细胞系中的表达及启动子CpG岛甲基化状态及其临床意义。
选取10例非血液系统疾病患者作为对照组,选取对照组骨髓细胞以及HL-60、K562细胞;采用荧光定量PCR检测骨髓细胞、HL-60和K562细胞系中miR-34b的相对表达量,采用甲基化特异性PCR检测miR-34b甲基化状态,对HL-60和K562细胞系用阿扎胞苷处理,再用相同方法检测2种细胞系中miR-34b的表达水平及甲基化状态。将Has-miR-34b转染至K562细胞,分为未转染组、阴性对照组和Has-miR-34b转染组;若转染成功,记录培养不同时间点的细胞增殖情况,并计算增殖抑制率。
对照组miR-34b相对表达水平为(5.23±0.75),HL-60为(0.05±0.01),K562为(0.04±0.01)。3组间差异有统计学意义(F=44.812,P<0.01)。HL-60和K562细胞系中CpG岛启动子区域呈甲基化状态,而10例非血液系统疾病患儿的骨髓细胞未甲基化。经阿扎胞苷处理后,HL-60和K562细胞系中miR-34b表达水平显著升高(P<0.05),且发现白血病细胞系启动子区域CpG岛甲基化在阿扎胞苷处理前后有变化,给药后甲基化显著降低,提示阿扎胞苷对启动子区域CpG岛甲基化有抑制作用。培养48、72、96和120小时后,Has-miR-34b转染组细胞增殖率分别为24.8%、46.7%、33.6%和4.7%,显著低于未转染组(P<0.05)。
白血病细胞系中miR-34b启动子区域CpG岛甲基化可降低miR-34b表达水平,这也是miR-34b能减弱对细胞增殖抑制作用的原因,因此miR-34b可能是参与白血病调控的抑癌基因。